We are live on
!
Find out more
MIM
MetLife Investment Management Portfolio holdings
AUM
$19.6B
1-Year Est. Return
32.64%
This Fund
S&P 500
This Quarter
Est. Return
+13.16%
1 Year Est. Return
+32.64%
3 Year Est. Return
+107.14%
5 Year Est. Return
+140.16%
10 Year Est. Return
–
AUM
$14.9B
AUM Growth
+$995M
(+7.2%)
Cap. Flow
-$291M
Cap. Flow
% of AUM
-1.95%
Top 10 Holdings %
Top 10 Hldgs %
26.38%
Holding
2,856
New
31
Increased
336
Reduced
1,500
Closed
71
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$128M |
| 2 |
LTHM
Livent Corporation
LTHM
|
+$15M |
| 3 |
State Street SPDR S&P MIDCAP 400 ETF Trust
MDY
|
+$12.3M |
| 4 |
iShares Russell 1000 Growth ETF
IWF
|
+$12.2M |
| 5 |
P
Everpure Inc
P
|
+$7.04M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$28.4M |
| 2 |
Microsoft
MSFT
|
+$25.6M |
| 3 |
NVIDIA
NVDA
|
+$15.2M |
| 4 |
Amazon
AMZN
|
+$11.2M |
| 5 |
iShares Russell 2000 ETF
IWM
|
+$10.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.53% |
| 2 | Financials | 12.17% |
| 3 | Healthcare | 11.68% |
| 4 | Consumer Discretionary | 10.99% |
| 5 | Industrials | 9.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
PSTX
2651
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
| $75.4K | ﹤0.01% |
23,645
-12,664
| -35% | -$42.2K |
|
2652
Willis Lease Finance
WLFC
$1.21B
| $74.9K | ﹤0.01% |
4,527
| – | – |
|
2653
FuelCell Energy
FCEL
$1.73B
| $74.6K | ﹤0.01% |
2,091
-5,859
| -74% | -$216K |
|
2654
Inspired Entertainment
INSE
$163M
| $74.2K | ﹤0.01% |
7,529
-4,519
| -38% | -$42.2K |
|
2655
Atlanticus Holdings
ATLC
$1.48B
| $74K | ﹤0.01% |
2,502
| – | – |
|
2656
Certara
CERT
$1.22B
| $73.5K | ﹤0.01% |
4,113
+11
| +0.3% | +$190 |
|
2657
Escalade
ESCA
$284M
| $73.5K | ﹤0.01% |
5,346
| – | – |
|
2658
Information Services Group
III
$249M
| $73.1K | ﹤0.01% |
18,099
-347
| -2% | -$1.5K |
|
2659
Omeros
OMER
$992M
| $72.8K | ﹤0.01% |
21,116
-11,150
| -35% | -$42.4K |
|
2660
IBEX
IBEX
$470M
| $72.6K | ﹤0.01% |
4,706
| – | – |
|
|
PWOD
2661
DELISTED
Penns Woods Bancorp
PWOD
| $71.9K | ﹤0.01% |
3,703
| – | – |
|
2662
HF Foods Group
HFFG
$99.2M
| $71.2K | ﹤0.01% |
20,342
-284
| -1% | -$1.24K |
|
2663
Children's Place
PLCE
$55.1M
| $71K | ﹤0.01% |
6,154
| – | – |
|
2664
AngioDynamics
ANGO
$651M
| $70.8K | ﹤0.01% |
12,066
-7,585
| -39% | -$45.1K |
|
|
KYNB
2665
Kyntra Bio
KYNB
$28.7M
| $70.5K | ﹤0.01% |
+1,200
| New | +$51.7K |
|
|
IGMS
2666
DELISTED
IGM Biosciences
IGMS
| $69.9K | ﹤0.01% |
+7,248
| New | +$84K |
|
2667
Fortrea Holdings
FTRE
$1.74B
| $69.3K | ﹤0.01% |
1,726
+4
| +0.2% | +$139 |
|
2668
Funko
FNKO
$331M
| $69.1K | ﹤0.01% |
11,079
-6,716
| -38% | -$47.1K |
|
2669
Ooma
OOMA
$553M
| $68.9K | ﹤0.01% |
8,073
-4,810
| -37% | -$47.9K |
|
|
CWBC
2670
Community West Bancshares
CWBC
$701M
| $68.6K | ﹤0.01% |
3,447
-1,973
| -36% | -$38K |
|
2671
Zevra Therapeutics
ZVRA
$679M
| $68.4K | ﹤0.01% |
11,792
-6,672
| -36% | -$41K |
|
|
TSE
2672
DELISTED
Trinseo
TSE
| $68.3K | ﹤0.01% |
18,073
-1,004
| -5% | -$5.36K |
|
2673
AlTi Global
ALTI
$457M
| $67.9K | ﹤0.01% |
11,993
| – | – |
|
2674
Credit Acceptance
CACC
$5.99B
| $67.8K | ﹤0.01% |
123
+1
| +0.8% | +$549 |
|
2675
Gevo
GEVO
$391M
| $67.7K | ﹤0.01% |
88,068
-23,474
| -21% | -$20.4K |
|
Similar funds
SPIA
BG
PCM
CS
HHII
LF
EIM
MetLife Investment Management's Q1 2024 Portfolio in Review
As of Q1 2024, MetLife Investment Management held 2,856 positions worth $14.9B, up 7.2% from $13.9B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
Trading was light in Q1 2024: portfolio turnover was 3.6%. MetLife Investment Management opened 31 new positions and exited 71, leaving the 2,856-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 28% of assets, up from 27% a quarter earlier, followed by Financials and Healthcare.
- MetLife Investment Management's largest Q1 2024 buy was Flutter Entertainment: 9,898 shares worth $1.98M.
- MetLife Investment Management added most to State Street SPDR S&P 500 ETF Trust in Q1 2024, an estimated $128M increase.
- MetLife Investment Management's biggest Q1 2024 reduction was Apple, cutting an estimated $28.4M.
- MetLife Investment Management fully exited Immunogen Inc in Q1 2024, selling an estimated $3.72M.
- MetLife Investment Management's ten largest holdings make up 26% of its $14.9B portfolio in Q1 2024.
- MetLife Investment Management opened 31 new positions and closed 71 in Q1 2024.
- MetLife Investment Management's portfolio value rose 7.2% quarter-over-quarter to $14.9B.
Based on MetLife Investment Management's 13F filing for Q1 2024, filed 14 May 2024.